<DOC>
	<DOCNO>NCT01802866</DOCNO>
	<brief_summary>The purpose study determine emixustat hydrochloride ( ACU-4429 ) reduce rate progression geographic atrophy compare placebo subject dry age-related macular degeneration .</brief_summary>
	<brief_title>Safety Efficacy Assessment Treatment Trials Emixustat Hydrochloride</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>1 . Males female , age â‰¥55 year . 2 . Clinical diagnosis GA associate AMD 3 . Able willing provide write informed consent . 4 . Able reliably administer oral medication self available assistance . 1 . Active CNV presence active ocular disease . 2 . Known serious allergy fluorescein sodium injection angiography . 3 . Prespecified laboratory abnormality screen . 4 . Treatment investigational study drug within 30 day screen device ( within 60 day screen ) 5 . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find 6 . Female subject pregnant lactating . 7 . Female subject childbearing potential male subject surgically sterile willing practice medically accept method birth control screen 30 day completion study . 8 . Unstable poorly control medical ophthalmic condition</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Geographic atrophy</keyword>
	<keyword>GA</keyword>
	<keyword>Dry AMD</keyword>
</DOC>